Skip to main content
. 2021 Jun 11;7(24):eabe6627. doi: 10.1126/sciadv.abe6627

Fig. 4. In vivo efficacy.

Fig. 4

(A to C) DOCTOR prevents progression of cSCC lesions and enhanced survival by 65% (P < 0.0001) at extremely low doses (0.003 mg/ml or 0.016 mg/kg) of DOX in DOCTOR. Error bars represent means ± SEM (n = 9). (D) cSCC tumors showing nuclear and cytoplasmic immunostaining (golden brown) for cleaved caspase-3 depicting apoptotic tumor cell death on treatment with DOCTOR R15 (scale bar, 50 μm). Photo credit: (C) B.R.S. and K.Y.T., H. Lee Moffitt Cancer Center and Research Institute; V.K., Harvard University; (D) V.K., Harvard University.